Category 2
34 In relation to category 2 the respondents submitted that the documents supporting the applicant's participation in various trials and assessments to demonstrate and verify the energy saving benefits of standby power controllers were relevant to the respondents' claim that the claims merely defined features which were known to those skilled in the art before the priority date; that the claims did not secure the promised advantage of the specification which was an enhancement of energy saving by networking of a plurality of energy saving devices; that claims 2 and 3 of the 197 patent were not novel when compared with the prior art base by reason of the installation in Victoria since at least as early as August 2011 of the Embertec EmberPlug; that claim 4 of the 624 patent was not novel by reason of the installation in Victoria since at least as early as August 2011 of the Embertec EmberPlug; that none of the claims was novel when compared with the prior art base; and that claims 1, 2 and 3 of the 624 patent were not novel when compared with the prior art base. The respondents submitted that the documents would provide evidence of the operation of the energy saving features of the applicant's SPC devices and went to the question of whether the products sold by the applicant were capable of being within the scope of the claims of the patents. In any event, the respondents submitted, documents concerning any test to evaluate or determine the validity of the patent in any respect falling within any of the grounds in issue on the pleadings should be discovered: F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295 at [16].
35 In oral submissions the respondents contended the category sought working notes, trial and assessment criteria, trial and assessment results, correspondence referring to Embertec's participation in trials and assessments, but only insofar as that correspondence demonstrated or verified the energy saving benefits of SPCs. Ordinarily, they submitted, one might think that in a case where, first, novelty and, second, sufficiency were in issue, the experimental work of the applicant who was the holder of the patent would be directly relevant. The respondents referred to F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295 and to Lubrizol Corporation Inc v Imperial Chemical Industries Plc (2000) 50 IPR 526 at [27]. The respondents raised novelty issues, questions of fair basing and questions of sufficiency. All three, it was submitted, would give rise to an obligation to discover the experimental work that led to the alleged development of both the patents and of the Emberplug product which was said to be the cause of the damage incurred.
36 The respondents submitted it would be expected, objectively, that in the working notes, trial and assessment criteria it was highly likely documents would be uncovered which went to the applicant's state of knowledge of the prior art in the period up to the priority date at the time it was developing both its product and the patents. So, on relevance, the respondents submitted that there was clearly relevance in relation to the novelty claims, which they pressed. This category was also likely to go to the question of why the Emberplug did not achieve that which the patents claim in the body of the specification, being the ability to network a plurality of devices. Documents created post the priority date may well shed light on the state of knowledge of Embertec prior to 3 June 2009. There was nothing to say that a field trial working note from some time shortly after or after the priority date may not make complete reference to Embertec's knowledge of the prior art in the period prior to 3 June 2009 and could operate, therefore, as an admission.
37 The fair basing issue arose because the respondents' case, in part, was that the claims were not fairly based on the matter described in the specifications. In particular, the body of the patent seemed to be directed almost entirely towards networking multiple energy saving devices and thereby achieving an energy saving benefit, but the claims of the patent were totally unrelated to the networking function claims of each patent, 624 and 197. Further, the Emberplug, which was the product sold by the applicant in the market, was a standalone device which was not networked in any way and could not connect to devices without the connection of a further power board of an ordinary type. So the Emberplug had no networking yet that was the very essence of the body of the specification of the patents.
38 The applicant submitted that category 2 was unconstrained as to time. As sworn by Mr Sloan, Embertec had been involved in trials and assessments to verify the energy saving benefits of its SPC products over a number of years. Those trials and assessments were ongoing. This category would capture every document created by the applicant relating to every test conducted, in the development of every version of the SPCs, to demonstrate the energy saving benefits of them. The category was opposed on the grounds that it was neither relevant nor necessary to the disposition of the proceedings and that it was unduly broad and oppressive. Documents recording trials and assessments carried on prior to the priority date could have no relevance to the allegations of lack of fair basis, novelty and innovative step, as pleaded. A fortiori documents recording trials and assessments carried on after the priority date could have no relevance to those issues.
39 In contrast to the position in F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295, the discovery sought in the present case did not relate to tests conducted by the party alleging invalidity but instead to tests conducted by the patent holder, and questions of misrepresentation and state of knowledge were not pleaded and did not arise. As to breadth and oppressiveness, on the evidence discovery would take one person approximately six weeks to complete. Such an exercise was unwarranted, unnecessary and disproportionate to any discernible benefit from the giving of discovery within this category.
40 In oral submissions in relation to category 2, the applicant submitted that there was currently no pleaded issue that Embertec was engaged in the conduct of tests or other work prior to the priority date 3 June 2009, which might impugn novelty or innovative step. Instead the allegation in the cross-claim was that the relevant patents lack novelty and innovative step, obviousness not being a matter that arose because these were innovation patents, s 7 of the Patents Act 1990 (Cth). The respondents' case was that there were numerous items of prior art which were in the public domain prior to the priority date and that those items, when analysed, demonstrated that the patents were not novel. For example, a listing of the relevant prior art was set out in paragraphs 18.3B, 18.4, 18.5, 19.5 and 19.6 of the statement of cross-claim. Each of those paragraphs collected and identified with great precision a number of items of prior art which were identified. That was where the battle lines were drawn and on that basis it was difficult to see that the trials and tests and the like carried out or possibly carried out by the applicant prior to the priority date would have any relevance.
41 For example, Burchett J in F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295 at [4] referred to what was described by Hoffman LJ in Unilever Plc v Chefaro Proprietaries Ltd [1994] FSR 135 at 142 as being standard practice to ask for discovery of the research and development which went into the defendant's product:
The object is to demonstrate, by reference to the work of the defendant's own researchers, that the subject-matter of the patent could not have been obvious to them.
In other words, the applicant submitted, if the first respondent was engaging in research and development, that tended to suggest against a finding of obviousness. But obviousness did not arise in the present case.
42 In F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295 at [4] Burchett J also referred to Aickin J's comment in Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 at 283 that the issue of obviousness "must be judged at the priority date", so that the discovery of documents by a patentee on this ground should be limited to a period ending then.
43 As to novelty, in F Hoffman-La Roche AG v Chiron Corporation (2000) 171 ALR 295 at [5] Burchett J referred to Aickin J's comment in Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 at 275 that:
It is indeed difficult to imagine a situation in which prior experiments as such could throw any light on novelty.
44 Turning to the question of fair basis, at [5] Burchett J said:
Similarly, with respect to fair basis, it is stated in Terrell on the Law of Patents (14th ed, 1994) at para 12.148:
The question of fair basis is entirely a matter of construction for the court. The fact that foreign patents had claims which were more restricted is irrelevant and accordingly documents which related to the restriction of the claims in other jurisdictions are not discoverable.
For this proposition, the authority cited is Schering Agrochemicals Ltd v ABM Chemicals Ltd [1987] RPC 185, where Falconer J said (at 187):
[T]he question of lack of fair basis is entirely a matter of construction for the court
…
I think that such documents cannot be of any possible relevance to the matter which the court has to decide on the issue of lack of fair basis. What the plaintiffs or any of their officers or people acting on their behalf may have thought about the extent of the disclosure or the width of the claim is nihil ad rem to what this court has to decide on this objection. It is a matter for the court to decide what is the construction of the claim and its ambit. It is a matter for the court to decide, as a matter of construction, what is the disclosure and its extent and thereafter to decide whether there is fair basis or not and what some person may or may not have thought, either in the plaintiffs' employ or engaged on behalf of the plaintiffs or indeed, if I may say so, some foreign patent office, has got nothing to do with that and cannot be of any assistance to the court.
The applicant submitted that this was exactly what the case was here. There were allegations of lack of fair basis and the Court would have to construe the patent and decide as a matter of construction whether the claims made in the patent were referrable to and squarely based upon the text of the specification. That exercise would not be assisted at all by discovery.
45 As to sufficiency as a justification for category 2, the applicant submitted, the actual paragraphs of the cross-claim in which sufficiency was raised were paragraphs 18.2 and 19.2 and it was difficult to see how discovery in the terms sought in category 2 could throw any light on the resolution of those paragraphs. For example, 19.2 merely recited matters in the claims for the 624 patent that were said to be not clear.
46 As to oppression, the applicant again referred to Mr Sloan's evidence.
47 The applicant submitted, the combination of the lack of relevance of the category with the burden imposed meant that the discovery was disproportionate to any forensic value that the documents might have and should be rejected.
48 In my opinion, as framed this category is insufficiently relevant to warrant an order for discovery. This category should be limited as follows
2. Working Notes, Trial and Assessment Criteria, Trial and Aassessment Rresults as at the priority date showing , and all correspondence referring to Embertec's participation in various trials and assessments in order to demonstrate and verify the energy saving benefits of the applicant's SPCs the subject of the patents in issue.
It is a matter of speculation whether there are any results after the priority date in the possession of the applicant which refer back to other pre-priority date results which in turn may assist the respondents: see Gambro Pty Ltd v Fresenius Medical Care Australia Pty Ltd [2001] FCA 235 at [11] per Tamberlin J.